NCT01790672

Brief Summary

The study is aimed at establishing the contribution of wine components on hydroxytyrosol body concentrations and biological effects.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P50-P75 for phase_1

Timeline
Completed

Started May 2011

Typical duration for phase_1

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2011

Completed
1.8 years until next milestone

First Submitted

Initial submission to the registry

February 11, 2013

Completed
2 days until next milestone

First Posted

Study publicly available on registry

February 13, 2013

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2013

Completed
Last Updated

July 24, 2014

Status Verified

July 1, 2014

Enrollment Period

2.3 years

First QC Date

February 11, 2013

Last Update Submit

July 23, 2014

Conditions

Keywords

AntioxidantsCentral Nervous System AgentsWine

Outcome Measures

Primary Outcomes (1)

  • Hydroxytyrosol biological fluids concentrations

    Hydroxytyrosol concentrations in plasma and urine

    0-24h after administration

Secondary Outcomes (10)

  • Ethanol concentration

    0-6h after administration

  • Subjective drunkenness

    0-6h after administration

  • Vital signs

    0-24h after administration

  • Ethanol metabolites concentrations

    0-24h after administration

  • Dopamine metabolites concentrations

    0-24h after administration

  • +5 more secondary outcomes

Study Arms (4)

Water

PLACEBO COMPARATOR

Lemon-flavored water. 293 ml in pilot A, 147 ml in pilot B, 235 ml in pilot C, 147 ml in the definitive study.

Other: Water

Alcoholized wine

ACTIVE COMPARATOR

Wine 13º in pilot A (293 ml), B (147 ml) and the definitive study (147 ml). Corresponding to 30 g of ethanol in pilot A, 15 g of ethanol in pilot B and 15 g of ethanol in the definitive study. Wine 8º in pilot C (235 ml). Corresponding to 15 g of ethanol.

Dietary Supplement: Alcoholized wine

De-alcoholized wine

PLACEBO COMPARATOR

Wine 0º. Pilot A: 293ml; pilot B: 147 ml; pilot C: 235 ml; definitive study: 147 ml. Corresponding to 0 g of ethanol.

Dietary Supplement: De-alcoholized wine

Ethanol

ACTIVE COMPARATOR

Ethanol 13º in pilot A (293 ml), B (147 ml) and definitive study (147 ml). Corresponding to 30 g of ethanol in pilot A, 15 g of ethanol in pilot B and in the definitive study. Ethanol 8º in pilot C (235 ml). Corresponding to 15 g of ethanol. Ethanol was administered as a single dose of Vodka Absolut (40º) diluted in lemon-flavored water.

Dietary Supplement: Ethanol

Interventions

EthanolDIETARY_SUPPLEMENT

Vodka Absolut

Ethanol
WaterOTHER

Lemon-flavored water

Water
Alcoholized wineDIETARY_SUPPLEMENT

Wine 13º or wine 8º

Alcoholized wine
De-alcoholized wineDIETARY_SUPPLEMENT

Wine 0º

De-alcoholized wine

Eligibility Criteria

Age18 Years - 55 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Understanding and accepting the study procedures and signing the informed consent.
  • Male and female volunteers aged 18 to 55 years. No fixed sex ratio has been established.
  • Clinical history and physical examination demonstrating no organic or psychiatric disorders.
  • The ECG and general blood and urine laboratory tests performed before the study should be within normal ranges. Minor or occasional changes from normal ranges are accepted if, in the investigator's opinion, considering the current state of the art, they are not clinically significant, are not life-threatening for the subjects and do not interfere with the product assessment. These changes and their non-relevance will be justified in writing specifically.
  • The body mass index (BMI=weigh/height2) will range from 19 to 25 kg/m2, and the weight from 50 to 100 kg. 25-27 could be accepted.
  • Women with regular menstrual cycle of 26-32 days.
  • Subjects socially drinking and who had ingested wine at least once.

You may not qualify if:

  • History or clinical evidence of gastrointestinal, liver, renal or other disorders which may lead to suspecting a disorder in drug absorption, distribution, metabolism or excretion, or that suggest gastrointestinal irritation due to drugs.
  • History or clinical evidence of psychiatric disorders, alcoholism, drug abuse, or regular use of psychoactive drugs.
  • Blood donation in the previous 8 weeks or participation in other clinical trials with drugs in the previous 12 weeks.
  • Having suffered any organic disease or major surgery in the three months prior to the study start.
  • Subjects with intolerance or serious adverse reactions to ethanol.
  • Taking more than 20 g of alcohol a day in women and more than 30 g in men.
  • Taking more than 5 coffees, teas, cola drinks or other stimulating drinks or with xanthines daily in the 3 months prior to the study start.
  • Subjects unable to understand the nature, consequences of the study and the procedures requested to be followed.
  • Smokers or ex-smokers of less than one year.
  • Subjects with positive serology to Hepatitis B, C or HIV.
  • Pregnant or nursing women or positive pregnancy test in urine. Women not undertaking to follow reliable contraceptive measures during the study (such as abstinence, hormonal contraceptives, intrauterine devices, double-barrier methods or vasectomised partner).
  • Women with amenorrhea or premenstrual syndrome of moderate or severe intensity.
  • Nonsteroidal anti-inflammatory drugs, antioxidants or vitamins consumption in the last 2 weeks.
  • Total cholesterol \>6.00 mmol/l (240 mg/dl) or triglycerides \>2.26 mmol/l (200 mg/dl).
  • Vegetarians or subjects following aberrant diets.
  • +2 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Parc de Salut Mar

Barcelona, Barcelona, 08003, Spain

Location

MeSH Terms

Interventions

EthanolWater

Intervention Hierarchy (Ancestors)

AlcoholsOrganic ChemicalsHydroxidesAlkaliesInorganic ChemicalsAnionsIonsElectrolytesOxidesOxygen Compounds

Study Officials

  • Magí Farré, MD, PhD

    Parc de Salut Mar

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
BASIC SCIENCE
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 11, 2013

First Posted

February 13, 2013

Study Start

May 1, 2011

Primary Completion

September 1, 2013

Study Completion

September 1, 2013

Last Updated

July 24, 2014

Record last verified: 2014-07

Locations